Becton, Dickinson and Company (NYSE: BDXB) Stock Competitors & Peer Comparison
See BDXB's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BDXB and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
| AVTR | $11.44 | +0.79% | 7.8B | 13.46 | $0.85 | N/A |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
BDXB vs BDX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas BDX's P/E ratio is 11.62. In terms of profitability, BDXB's ROE is +0.05%, compared to BDX's ROE of +0.05%. Regarding short-term risk, BDXB is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
BDXB vs BDXA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas BDXA's P/E ratio is 45.70. In terms of profitability, BDXB's ROE is +0.05%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, BDXB is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
BDXB vs MDLN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas MDLN's P/E ratio is 45.06. In terms of profitability, BDXB's ROE is +0.05%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, BDXB is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
BDXB vs WST Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas WST's P/E ratio is 41.19. In terms of profitability, BDXB's ROE is +0.05%, compared to WST's ROE of +0.19%. Regarding short-term risk, BDXB is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
BDXB vs HOLX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BDXB's ROE is +0.05%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BDXB is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
BDXB vs COO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas COO's P/E ratio is 15.42. In terms of profitability, BDXB's ROE is +0.05%, compared to COO's ROE of +0.03%. Regarding short-term risk, BDXB is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check COO's competition here
Baxter International Inc. (NYSE: BAX)
BDXB vs BAX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas BAX's P/E ratio is 10.77. In terms of profitability, BDXB's ROE is +0.05%, compared to BAX's ROE of -0.16%. Regarding short-term risk, BDXB is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
BDXB vs ATR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ATR's P/E ratio is 23.13. In terms of profitability, BDXB's ROE is +0.05%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BDXB is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
BDXB vs AVTR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas AVTR's P/E ratio is 13.46. In terms of profitability, BDXB's ROE is +0.05%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BDXB is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
BDXB vs RGEN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas RGEN's P/E ratio is 73.31. In terms of profitability, BDXB's ROE is +0.05%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BDXB is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
BDXB vs TFX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas TFX's P/E ratio is 12.32. In terms of profitability, BDXB's ROE is +0.05%, compared to TFX's ROE of -0.28%. Regarding short-term risk, BDXB is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
BDXB vs BLCO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas BLCO's P/E ratio is 24.88. In terms of profitability, BDXB's ROE is +0.05%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BDXB is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
BDXB vs STVN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas STVN's P/E ratio is 31.81. In terms of profitability, BDXB's ROE is +0.05%, compared to STVN's ROE of +0.10%. Regarding short-term risk, BDXB is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
BDXB vs MMSI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas MMSI's P/E ratio is 19.01. In terms of profitability, BDXB's ROE is +0.05%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BDXB is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
BDXB vs ICUI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ICUI's P/E ratio is 19.66. In terms of profitability, BDXB's ROE is +0.05%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, BDXB is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
BDXB vs HAE Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas HAE's P/E ratio is 15.86. In terms of profitability, BDXB's ROE is +0.05%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BDXB is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
BDXB vs XRAY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas XRAY's P/E ratio is 9.04. In terms of profitability, BDXB's ROE is +0.05%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, BDXB is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
BDXB vs LMAT Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas LMAT's P/E ratio is 37.05. In terms of profitability, BDXB's ROE is +0.05%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BDXB is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
BDXB vs PLSE Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas PLSE's P/E ratio is -27.48. In terms of profitability, BDXB's ROE is +0.05%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, BDXB is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
BDXB vs ATRC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, BDXB's ROE is +0.05%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, BDXB is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
BDXB vs BLFS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas BLFS's P/E ratio is -141.85. In terms of profitability, BDXB's ROE is +0.05%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, BDXB is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
BDXB vs AZTA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas AZTA's P/E ratio is 60.82. In terms of profitability, BDXB's ROE is +0.05%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, BDXB is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
BDXB vs KMTS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas KMTS's P/E ratio is -8.92. In terms of profitability, BDXB's ROE is +0.05%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, BDXB is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
BDXB vs STAA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas STAA's P/E ratio is 41.02. In terms of profitability, BDXB's ROE is +0.05%, compared to STAA's ROE of -0.06%. Regarding short-term risk, BDXB is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
BDXB vs QDEL Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas QDEL's P/E ratio is 11.98. In terms of profitability, BDXB's ROE is +0.05%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, BDXB is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
BDXB vs ATRI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BDXB's ROE is +0.05%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BDXB is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
BDXB vs ANGO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ANGO's P/E ratio is -34.85. In terms of profitability, BDXB's ROE is +0.05%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BDXB is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
BDXB vs NNNN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NNNN's P/E ratio is 145.38. In terms of profitability, BDXB's ROE is +0.05%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BDXB is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
BDXB vs OSUR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas OSUR's P/E ratio is -4.78. In terms of profitability, BDXB's ROE is +0.05%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, BDXB is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
BDXB vs SMTI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas SMTI's P/E ratio is -426.00. In terms of profitability, BDXB's ROE is +0.05%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, BDXB is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
BDXB vs UTMD Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas UTMD's P/E ratio is 19.86. In terms of profitability, BDXB's ROE is +0.05%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BDXB is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BDXB vs INFU Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas INFU's P/E ratio is 23.97. In terms of profitability, BDXB's ROE is +0.05%, compared to INFU's ROE of +0.14%. Regarding short-term risk, BDXB is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
BDXB vs KRMD Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas KRMD's P/E ratio is -95.75. In terms of profitability, BDXB's ROE is +0.05%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, BDXB is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
BDXB vs PDEX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas PDEX's P/E ratio is 19.34. In terms of profitability, BDXB's ROE is +0.05%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BDXB is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
BDXB vs MBOT Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas MBOT's P/E ratio is -6.58. In terms of profitability, BDXB's ROE is +0.05%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, BDXB is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
BDXB vs AKYA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BDXB's ROE is +0.05%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BDXB is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
BDXB vs STSS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas STSS's P/E ratio is -0.02. In terms of profitability, BDXB's ROE is +0.05%, compared to STSS's ROE of -1.66%. Regarding short-term risk, BDXB is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
BDXB vs DXR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas DXR's P/E ratio is 27.33. In terms of profitability, BDXB's ROE is +0.05%, compared to DXR's ROE of +0.22%. Regarding short-term risk, BDXB is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
BDXB vs OMIC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BDXB's ROE is +0.05%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BDXB is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
BDXB vs IGAP Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BDXB's ROE is +0.05%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, BDXB is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
BDXB vs NEPH Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NEPH's P/E ratio is 50.86. In terms of profitability, BDXB's ROE is +0.05%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, BDXB is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
BDXB vs MLSS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas MLSS's P/E ratio is -6.50. In terms of profitability, BDXB's ROE is +0.05%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, BDXB is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
BDXB vs POCI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas POCI's P/E ratio is -6.07. In terms of profitability, BDXB's ROE is +0.05%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BDXB is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
BDXB vs SDC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas SDC's P/E ratio is -0.03. In terms of profitability, BDXB's ROE is +0.05%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BDXB is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
BDXB vs HBIO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas HBIO's P/E ratio is -16.81. In terms of profitability, BDXB's ROE is +0.05%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, BDXB is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
BDXB vs IVC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas IVC's P/E ratio is -0.79. In terms of profitability, BDXB's ROE is +0.05%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BDXB is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
BDXB vs RVP Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas RVP's P/E ratio is -2.06. In terms of profitability, BDXB's ROE is +0.05%, compared to RVP's ROE of -0.08%. Regarding short-term risk, BDXB is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
BDXB vs ZJYL Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, BDXB's ROE is +0.05%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BDXB is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
BDXB vs FEMY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas FEMY's P/E ratio is -10.25. In terms of profitability, BDXB's ROE is +0.05%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, BDXB is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
BDXB vs RGNT Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas RGNT's P/E ratio is -0.08. In terms of profitability, BDXB's ROE is +0.05%, compared to RGNT's ROE of N/A. Regarding short-term risk, BDXB is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
BDXB vs NSTG Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BDXB's ROE is +0.05%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BDXB is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
BDXB vs NXGL Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NXGL's P/E ratio is -1.13. In terms of profitability, BDXB's ROE is +0.05%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, BDXB is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
BDXB vs POAI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas POAI's P/E ratio is -0.03. In terms of profitability, BDXB's ROE is +0.05%, compared to POAI's ROE of -107.05%. Regarding short-term risk, BDXB is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
BDXB vs LUCY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas LUCY's P/E ratio is -0.39. In terms of profitability, BDXB's ROE is +0.05%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, BDXB is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
BDXB vs MHUA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BDXB's ROE is +0.05%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BDXB is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
BDXB vs NXGLW Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, BDXB's ROE is +0.05%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, BDXB is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
BDXB vs GMVD Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BDXB's ROE is +0.05%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BDXB is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
BDXB vs GMVDW Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BDXB's ROE is +0.05%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BDXB is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
BDXB vs AVGR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BDXB's ROE is +0.05%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BDXB is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
BDXB vs LUCYW Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, BDXB's ROE is +0.05%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, BDXB is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
BDXB vs GCTK Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas GCTK's P/E ratio is -0.01. In terms of profitability, BDXB's ROE is +0.05%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, BDXB is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for BDXB.Check GCTK's competition here
IntriCon Corporation (NASDAQ: IIN)
BDXB vs IIN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas IIN's P/E ratio is 226.45. In terms of profitability, BDXB's ROE is +0.05%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BDXB is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check IIN's competition here
Apria, Inc. (NASDAQ: APR)
BDXB vs APR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, APR has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas APR's P/E ratio is 22.59. In terms of profitability, BDXB's ROE is +0.05%, compared to APR's ROE of +9.81%. Regarding short-term risk, BDXB is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check APR's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
BDXB vs ATRS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BDXB's ROE is +0.05%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BDXB is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check ATRS's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
BDXB vs HRC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas HRC's P/E ratio is 41.92. In terms of profitability, BDXB's ROE is +0.05%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BDXB is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
BDXB vs ALOG Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BDXB's ROE is +0.05%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BDXB is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
BDXB vs IVTY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDXB) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXB stands at 13.7B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BDXB is priced at $48.16 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXB currently has a P/E ratio of 7.60, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BDXB's ROE is +0.05%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BDXB is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BDXB.Check IVTY's competition here